CHEK1 and ovarian carcinoma: A recent study showed that targeting HMGB3 consumption by inhibiting ATR/CHK1/p-CHK1 DNA damage signaling pathway sensitizes chemotherapy-resistant ovarian cancer cells to cisplatin.88